FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 08/2022”. The Monitor is a month-to-month printed overview of enterprise capital developments within the European Life Sciences sector.
As of the top of August 2022 we establish the next present VC developments in Europe:
- In 2022, general Life Sciences funding has reached EUR 6,501m thus far
- Prime 5 Offers exceed EUR 120m every, largest transaction amounted to EUR 500m in Doctolib (France)
- Bpifrance (France) dominates the Prime 5 Traders (by deal quantity), adopted by Eurazeo (France) and Common Atlantic (United States)
- Biotech acquired 43% of the overall funding quantity, (+1% in comparison with the earlier month)
- Oncology nonetheless dominates as the highest indication in Biotechnology
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink